Phase 3 Studies Show Upadacitinib Effective for Non-Segmental Vitiligo

Results from two phase 3 randomized controlled studies (Viti-Up) published in The Lancet indicate that upadacitinib 15 mg daily provides clinically meaningful repigmentation for adults and adolescents with non-segmental vitiligo. The studies found significant improvements in both facial and total body repigmentation, with the safety profile consistent with previous observations for upadacitinib, and no new safety signals identified.